Supplementary Online Content

eTable 1. Mean SMI and SMD values classified by gender.
eTable 2. Primary outcomes of patients with gastric cancer who underwent surgical treatment.

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Mean SMI and SMD values classified by gender.

	SMI, cm²/m²[†]				SMD, HU[†]			
	All	Male	Female	*p*-value	All	Male	Female	*p*-value
Sarcopenia[†]	6.57 (0.96)	6.92 (0.91)	6.01 (0.77)	0.001[§]	32.67 (3.59)	33.98 (3.47)	30.56 (2.69)	0.001[§]
Nonsarcopenia[†]	9.30 (1.41)	9.92 (1.24)	8.29 (1.03)	< 0.001[§]	41.93 (4.11)	43.63 (3.35)	39.17 (3.75)	< 0.001[§]
Total[†]	8.62 (1.76)	9.18 (1.74)	7.72 (1.38)	< 0.001[§]	39.63 (5.65)	41.24 (5.37)	37.02 (5.13)	< 0.001[§]

SMI: skeletal muscle index; SMD: skeletal muscle density.

[†] Values are mean (standard deviation).

[§] Statistically significant.

eTable 2. Primary outcomes of patients with gastric cancer who underwent surgical treatment.

	Total	SMI-sarcopenia	SMI-nonsarcopenia	*p*-value	SMD-sarcopenia	SMD-nonsarcopenia	*p*-value
1-year OS	86.0%	80.7%	87.3%,		78.2%	88.0%	
3-year OS	67.7%	59.1%	70.3%	0.022[§]	50.4%	72.9%	0.028[§]
5-year OS	59.5%	48.2%	63.1%		45.7%	62.7%	
	Total	Sarcopenia	Nonsarcopenia	*p*-value	Sarcopenia	Nonsarcopenia	*p*-value
1-year PFS	83.8%	78.4%	85.1%		78.1%	85.2%	
3-year PFS	65.5%	58.1%	67.1%	0.058	50.3%	70.1%	0.054
5-year PFS	57.5%	46.0%	59.9%		45.6%	59.5%	

SMI: skeletal muscle index; SMD: skeletal muscle density; OS: overall survival; PFS: progression-free survival.
Overall survival and progression-free survival were analyzed by the Kaplan-Meier method and log-rank test.
[§] Statistically significant.